In fact, recent research demonstrated genotype-directed irinotecan dosing resulted in improved pathologic complete responses and decreased irinotecan-related toxicity for UGT1A1 intermediate metabolizers (*1/*28) undergoing neoadjuvant chemoradiation for locally advanced rectal cancer [25]. This evidence concerns the gene UGT1A1 and rectal cancer.